The Effect of Omega-3 Supplements on The Serum Levels Of ACE/ACE2 Ratio As A Potential Key in Cardiovascular Disease: A Randomized Clinical Trial in Participants with Vitamin D Deficiency

Main Article Content

Sara M. Daboul
Mohammad Abusamak
Beisan A. Mohammad
Ahmad R. Alsayed
Maha Habash
Ibrahim Mosleh
Sami Al-Shakhshir
Reem Issa
Mahmoud Abu-Samak


Omega-3, ACE, ACE2, ACE/ACE2 ratio, Non-HDL, Vitamin D, 25- hydroxy vitamin D (25OHD)


Objective: The aim of this randomized controlled clinical trial was to determine the effect of the omega-3 fatty acid supplementations 300 mg per day for 8 weeks on the serum levels of ACE/ACE2 ratio in Jordanian participants with vitamin D deficiency (VDD). Methods: The physical and clinical characteristic of individuals in both intervention and control randomized controlled clinical trial were measured and analyzed. The comparisons between the two groups and the changes in each group before and after taking omega-3 doses were studied through independent t test and paired t test, respectively. Possible factors that have a role in the changes were determined by multivariate stepwise regression. Follow-up period lasted 10 weeks. Results: The sample consisted of 82 participants with VDD and a mean age of 37.85 ± 9.85 years. Omega-3 Supplements resulted in a significant decrease in serum ACE levels, ACE/ACE2 ratio and serum 25-hydroxy vitamin D (25OHD). While the change in serum ACE2 levels and serum triglycerides levels were insignificant. Also, a significant increase in serum LDL levels were observed. Conclusion: It is possible that taking high doses of omega-3 fatty acid supplementations have positive effects on the heart and circulatory system and could protect from COVID-19 or decrease disease severity, in connection with a decrease in the ACE/ACE 2 ratio. On the other hand, omega-3 supplement may have negative effect on cardiovascular system due to the significant increase in serum LDL levels.

Abstract 695 | PDF Downloads 582


1. Mahmudpour M, Roozbeh J, Keshavarz M, et al. COVID-19 cytokine storm: The anger of inflammation. Cytokine. 2020;133(1):155151.
2. Chaudhary M. COVID-19 susceptibility: potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics. 2020;21(1):1-8.
3. Hess DC, Eldahshan W, Rutkowski E. COVID-19-Related Stroke. Translational Stroke Research. 2020;11(3):322-325.
4. Rico-Mesa JS, White A, Anderson AS. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB. Current Cardiology Reports. 2020;22(5):31.
5. Bosso M, Thanaraj TA, Abu-Farha M, et al. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19. Molecular therapy. Methods & Clinical Development. 2020;18(1):321-327. https://doi.
6. Verdecchia P, Cavallini C, Spanevello A, et al. The pivotal link between ACE2 deficiency and SARS-CoV-2 infection. European Journal of Internal Medicine. 2020;76(1):14-20.
7. Cole-Jeffrey CT, Liu M, Katovich MJ, et al. ACE2 and Microbiota: Emerging Targets for Cardiopulmonary  Disease Therapy. Journal of Cardiovascular Pharmacology. 2015;66(6):540-550.
8. Wang J, Li N, Gao F, et al. Balance between angiotensin converting enzyme and angiotensin converting enzyme 2 in patients
with chronic heart failure. Journal of the renin-angiotensin-aldosterone system. JRAAS. 2015;16(3):553-558.
9. Gómez J, Albaiceta GM, García-Clemente M, et al. Angiotensin-converting enzymes (ACE, ACE2) gene variants and COVID-19 outcome. Gene. 2020;762:145102.
10. Danser AHJ, Epstein M, Batlle D. Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension (Dallas, Tex.: 1979). 2020;75(6):1382-1385. https:// 
11. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. Journal of Medical Virology. 2020;92(9):726-730.
12. Viana SD, Nunes S, Reis F. ACE2 imbalance as a key player for the poor outcomes in COVID-19 patients with age-related comorbidities - Role of gut microbiota dysbiosis. Ageing Research Reviews. 2020;62:101123.
13. Alfasfos N, Darawad MW, Nofal B, et al. Knowledge, attitudes, beliefs and perceived risk of acute coronary syndrome among Jordanian patients. 2016;8(15):1830-1844.
14. von Schacky C, Harris WS. Cardiovascular benefits of omega-3 fatty acids. Cardiovascular research. 2007;73(2):310-315.
15. Covington MB. Omega-3 fatty acids. American family physician. 2004;70:133-140. 
16. Kumar KV, Das UN. Effect of cis-unsaturated fatty acids, prostaglandins, and free radicals on angiotensin-converting enzyme activity in vitro. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and
Medicine (New York, N.Y.). 1997;214(4):374-379. 
17. Hamden K, Keskes H, Belhaj S, et al. Inhibitory potential of omega-3 fatty and fenugreek essential oil on key enzymes of carbohydrate-digestion and hypertension in diabetes rats. Lipids in Health and Disease. 2011;10(1):226. https://doi.
18. Farooq MA, Gaertner S, Amoura L, et al. Intake of omega-3 formulation EPA:DHA 6:1 by old rats for 2 weeks improved endothelium-dependent relaxations and normalized the expression level of ACE/AT1R/NADPH oxidase and the formation of
ROS in the mesenteric artery. Biochemical Pharmacology. 2020;173(1):113749.
19. Borghi C, Cicero AF. Omega-3 polyunsaturated fatty acids: Their potential role in blood pressure prevention and management. Heart International. 2006;2(2):98.
20. Cabo J, Alonso R, Mata P. Omega-3 fatty acids and blood pressure. The British Journal of Nutrition. 2012;107 Suppl 2:S195-200.
21. Ulu A, Harris TR, Morisseau C, et al. Anti-inflammatory effects of ω-3 polyunsaturated fatty acids and soluble epoxide hydrolase inhibitors in angiotensin-II-dependent hypertension. Journal of Cardiovascular Pharmacology. 2013;62:285-297. https://doi.or
22. Theobald HE, Chowienczyk PJ, Whittall R, et al. LDL cholesterol-raising effect of low-dose docosahexaenoic acid in middle-aged men and women. The American Journal of Clinical Nutrition. 2004;79(4):558-563.
23. Mori TA, Burke V, Puddey IB, et al. Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum
lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men. The American Journal of Clinical Nutrition. 2000;7195):1085-1094.
24. Satoh N, Shimatsu A, Kotani K, et al. Purified eicosapentaenoic acid reduces small dense LDL, remnant lipoprotein particles, and C-reactive protein in metabolic syndrome. Diabetes Care. 2007;30:144-146.
25. Alhabeeb H, Kord-Varkaneh H, Tan SC, et al. The influence of omega-3 supplementation on vitamin D levels in humans: a systematic review and dose-response meta-analysis of randomized controlled trials. Critical Reviews in Food Science and
Nutrition. 2022;62(11):3116-3123.
26. Xu J, Yang J, Chen J, et al. Vitamin D alleviates lipopolysaccharide‑induced acute lung injury via regulation of the renin‑angiotensin system. Molecular Medicine Reports. 2017;16(5):7432-7438.
27. Mardani R, Alamdary A, Mousavi Nasab SD, et al. Association of vitamin D with the modulation of the disease severity in COVID-19. Virus research. 2020;289:198148.
28. Honardoost M, Ghavideldarestani M, Khamseh ME. Role of vitamin D in pathogenesis and severity of COVID-19 infection. Archives of Physiology and Biochemistry. 2020;1-7.
29. Martín Giménez VM, Inserra F, et al. Vitamin D deficiency in African Americans is associated with a high risk of severe disease and mortality by SARS-CoV-2. Journal of Human Hypertension. 2021;35(4):378-380.
30. Lin M, Gao P, Zhao T, et al. Calcitriol regulates angiotensin-converting enzyme and angiotensin converting-enzyme 2 in diabetic kidney disease. Molecular Biology Reports. 2016;43(5):397-406.
31. Cereda E, Bogliolo L, de Stefano L, et al. A brief discussion of the benefit and mechanism of vitamin D supplementation on coronavirus disease 2019. Current Opinion in Clinical Nutrition and Metabolic Care. 2021;24(1):102-107. https://doi.
32. Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford, England). 2018;57(2):ii43-ii50.
33. Bermudez EA, Rifai N, Buring J, et al. Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women. Arteriosclerosis, Thrombosis, And Vascular Biology. 2002;22(10):1668-1673. https://doi.
34. Kunutsor SK, Laukkanen JA. Should inflammatory pathways be targeted for the prevention and treatment of hypertension? Heart (British Cardiac Society). 2019;105(9):665-667.
35. Jayedi A, Rahimi K, Bautista LE, et al. Inflammation markers and risk of developing hypertension: a meta-analysis of cohort studies. Heart (British Cardiac Society). 2019;105(9):686-692.
36. Hallaj S, Ghorbani A, Mousavi-Aghdas SA, et al. Angiotensin-converting enzyme as a new immunologic target for the new SARS-CoV-2. Immunology and Cell Biology. 2021;99(2):192-205.

Most read articles by the same author(s)